Kymos Group — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kymos Group is a well-established, privately-held analytical CRO with a strong European footprint, offering end-to-end bioanalytical and CMC testing services to the global biopharmaceutical industry. Its core value proposition is built on regulatory rigor, scientific expertise across multiple molecule modalities, and a partnership-focused approach, supporting clients from early R&D through commercialization. Recent strategic acquisitions, such as Particle Analytical, have expanded its capabilities in particle analysis and solid-state characterization, strengthening its position as a comprehensive service provider in a competitive CRO market.

Drug DeliveryAnalytical Services

Technology Platform

Integrated suite of GLP/GMP-certified analytical methodologies for bioanalysis and CMC testing of small molecules, biologics, TIDES (oligonucleotides/peptides), and advanced therapies (nucleic acids, viral vectors, LNPs). Enhanced by particle analysis and solid-state characterization via acquisition.

Opportunities

Strong demand growth from the expanding markets for complex therapeutics like biologics, biosimilars, oligonucleotides, peptides, and advanced cell/gene therapies, which require specialized analytical expertise often outsourced to CROs.

The strategic acquisition of Particle Analytical expands its service portfolio and creates cross-selling opportunities, while its pan-European network positions it well for regional and global contracts.

Risk Factors

Revenue is tied to cyclical biopharma R&D spending and subject to intense competition from large global CROs and niche providers.

Operational and regulatory risk is high, as the business depends on maintaining flawless GLP/GMP certifications and a strong inspection history with agencies like the FDA and EMA.

Competitive Landscape

Kymos competes in a fragmented but competitive CRO market against large, full-service global players (e.g., LabCorp, IQVIA) and numerous specialized analytical laboratories. Its differentiation is based on deep expertise in specific modalities (TIDES, ATMPs), a strong European regulatory track record, and a partnership-oriented approach as a mid-sized specialist.

More companies in Small Molecule Drugs →More companies in Spain →